MRC Holland

MRC Holland is based in Amsterdam. It was founded by Dr. Jan Schouten in 1985 and initially focused on the production of restriction enzymes and molecular weight markers.

In 1997, the company’s focus shifted to developing new methods of DNA analysis. In 2002, the first article about multiplex ligation, dependent probe amplification, or MLPA®, was published. Since then, MLPA has become the ‘gold standard’ of detecting variations in the number of copies, with more than 350 samples available on the market.

MRC Holland continues to innovate in the field of development of the new MLPA assays, the improvement of existing assays, and the recent introduction of two new technologies.

In 2018, the first commercial spinal muscular Atrophy (SMA) screening kit for newborns was introduced. In 2020, digitalMLPA technology was introduced, which combines the proven quality of MLPA and the power of NGS technology to study a large number of sequences in a single study.